In both metastatic and early-stage HER2+ breast cancer treated with pertuzumab (Perjeta), the incidence of diarrhea is high (28%-72%), but dose-delays or discontinuations resulting from diarrhea are rare.
Why this matters
This study gives clinicians and patients information about the frequency and severity of diarrhea as an adverse effect of pertuzumab.
This study was a pooled analysis of a phase 3 trial of metastatic HER2+ cancer (CLEOPATRA, n=804) and 2 phase 2 trials (NeoSphere, n=416; TRYPHAENA, n=223).
Pertuzumab-based treatment had a high incidence of diarrhea (from 28% to 72%; grade 1, 21%-54%; grade 2, 8%-37%; grade 3, 0%-12%; grade 4, 0%).